|
Gene Therapy
Citations 301-310 of 434 total displayed.
|
Past content
(since Aug 1998):
|
Lentiviral vectors pseudotyped with a modified RD114 envelope glycoprotein show increased stability in sera and augmented transduction of primary lymphocytes and CD34+ cells derived from human and nonhuman primates
- Virginie Sandrin, Bertrand Boson, Patrick Salmon, Wilfried Gay, Didier Nègre, Roger Le Grand, Didier Trono, and François-Loïc Cosset
Blood 2002; 100: 823-832.
[Abstract]
[Full text]
[PDF]
Retroviral transduction of IL2RG into CD34+ cells from X-linked severe combined immunodeficiency patients permits human T- and B-cell development in sheep chimeras
- Emily J. Tsai, Harry L. Malech, Martha R. Kirby, Amy P. Hsu, Nancy E. Seidel, Christopher D. Porada, Esmail D. Zanjani, David M. Bodine, and Jennifer M. Puck
Blood 2002; 100: 72-79.
[Abstract]
[Full text]
[PDF]
Induction of T-cell tolerance to an MHC class I alloantigen by gene therapy
- Jessamyn Bagley, Chaorui Tian, David H. Sachs, and John Iacomini
Blood 2002; 99: 4394-4399.
[Abstract]
[Full text]
[PDF]
Adenovirus encoding vascular endothelial growth factor-D induces tissue-specific vascular patterns in vivo
- Tatiana V. Byzova, Corey K. Goldman, Jurek Jankau, Juhua Chen, Gustavo Cabrera, Marc G. Achen, Steven A. Stacker, Kevin A. Carnevale, Maria Siemionow, Steven R. Deitcher, and Paul E. DiCorleto
Blood 2002; 99: 4434-4442.
[Abstract]
[Full text]
[PDF]
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo
- Anja Ehrhardt and Mark A. Kay
Blood 2002; 99: 3923-3930.
[Abstract]
[Full text]
[PDF]
Functional amelioration of murine galactosialidosis by genetically modified bone marrow hematopoietic progenitor cells
- Thasia Leimig, Linda Mann, Maria del Pilar Martin, Erik Bonten, Derek Persons, James Knowles, James A. Allay, John Cunningham, Arthur W. Nienhuis, Richard Smeyne, and Alessandra d'Azzo
Blood 2002; 99: 3169-3178.
[Abstract]
[Full text]
[PDF]
Adapting a transforming growth factor  -related tumor protection strategy to enhance antitumor immunity
- Catherine M. Bollard, Claudia Rössig, M. Julia Calonge, M. Helen Huls, Hans-Joachim Wagner, Joan Massague, Malcolm K. Brenner, Helen E. Heslop, and Cliona M. Rooney
Blood 2002; 99: 3179-3187.
[Abstract]
[Full text]
[PDF]
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy
- Jane D. Mount, Roland W. Herzog, D. Michael Tillson, Susan A. Goodman, Nancy Robinson, Mark L. McCleland, Dwight Bellinger, Timothy C. Nichols, Valder R. Arruda, Clinton D. Lothrop, Jr, and Katherine A. High
Blood 2002; 99: 2670-2676.
[Abstract]
[Full text]
[PDF]
Efficient gene transfer into human primary blood lymphocytes by surface-engineered lentiviral vectors that display a T cell-activating polypeptide
- Marielle Maurice, Els Verhoeyen, Patrick Salmon, Didier Trono, Stephen J. Russell, and François-Loïc Cosset
Blood 2002; 99: 2342-2350.
[Abstract]
[Full text]
[PDF]
Successful treatment of murine -thalassemia intermedia by transfer of the human -globin gene
- Chad May, Stefano Rivella, Amy Chadburn, and Michel Sadelain
Blood 2002; 99: 1902-1908.
[Abstract]
[Full text]
[PDF]
|
|
